Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPAND trial in advanced gastric or gastroesophageal junction adenocarcinoma
NL-OMON31982Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2008
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of cetuximab, capecitabine and cisplatin, sponsored by Merck & Co. Started Sep 2008; status: active, not recruiting.
02
Drugs
cetuximabcapecitabinecisplatin
Beyond the preview
Go deeper on NL-OMON31982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31982.